Detail

Basic Information Clinical Results Relationship Graph

Gene symbol	STAT3	Synonyms	ADMIO, ADMIO1, APRF, HIES	Type of gene	protein-coding
Chromosome	17	Map location	17q21.2	dbXrefs
Gene perturbation-related omics dataset	PerturbAtlas \| PertOrg
Description	signal transducer and activator of transcription 3

GTO ID	GTC1815
Trial ID	NCT03334617
Disease	Non Small Cell Lung Cancer
Altered gene	STAT3
Therapeutic/Target gene	Target gene
Therapy	ASO
Treatment	ISIS-STAT3rx\|AZD9150\|ISIS 481464\|IONIS-STAT3-2.5Rx
Phase	Phase2
Recruitment status	Active, Not Recruiting
Title	An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients With Non-Small Cell Lung Cancer, Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON)
Year	2017
Country	Austria\|Canada\|France\|Germany\|Israel\|Korea, Republic of\|Spain\|United States
Company sponsor	AstraZeneca
Other ID(s)	D6185C00001\|138050\|2023-509004-15-00\|2017-002208-28

Vector information

Vector	No vector was used

Cohort1: Durvalumab_Olaparib

Administration route	intravenous infusion\|oral
Dosage	Durvalumab, 1500 mg, Q4W ±2 days\|Olaparib, 300 mg BD
Age	Adult, Older_Adult

Cohort2: Durvalumab_AZD9150

Administration route	intravenous infusion
Dosage	Durvalumab, 1500 mg, Q4W ±2 days\|AZD9150, 200 mg, QW, every other day of a 1-week lead-in period followed
Age	Adult, Older_Adult

Cohort3: Durvalumab_AZD6738_twice daily in Cycle 0 Days 1-7

Administration route	intravenous infusion\|oral
Dosage	Durvalumab, 1500 mg, Q4W ±2 days\|AZD6738, 240 mg, twice daily in Cycle 0 Days 1-7, followed by 7 days on treatment in each cycle between Days 22-28
Age	Adult, Older_Adult

Cohort4: Durvalumab_Vistusertib

Administration route	intravenous infusion\|oral
Dosage	Durvalumab, 1500 mg, Q4W ±2 days\|Vistusertib, 125 mg BD
Age	Adult, Older_Adult

Cohort5: Durvalumab_Oleclumab

Administration route	intravenous infusion
Dosage	Durvalumab, 1500 mg, Q4W ±2 days\|Oleclumab, dose level 1 for 2 cycles and then dose level 2 thereafter
Age	Adult, Older_Adult

Cohort6: Durvalumab_trastuzumab

Administration route	intravenous infusion
Dosage	Durvalumab, 1120mg, Q3W ±2 days\|trastuzumab, 5.4 mg, Q3W ±2 days
Age	Adult, Older_Adult

Cohort7: Durvalumab_cediranib

Administration route	intravenous infusion\|oral
Dosage	Durvalumab, 1500 mg, Q4W ±2 days\|cediranib, 20 mg, on an intermittent schedule (5 days on, 2 days off), starting on C1D1
Age	Adult, Older_Adult

Cohort8: AZD6738_dose level2_twice daily for 14 days

Administration route	oral
Dosage	AZD6738, 240 mg, twice daily for 14 days on treatment in each 28-day cycle, between Days 1 and 14
Age	Adult, Older_Adult

Cohort9: Durvalumab_AZD6738_twice daily for 14 days in each 28 day cycle

Administration route	intravenous infusion\|oral
Dosage	Durvalumab, 1500 mg, Q4W ±2 days\|AZD6738, 240 mg, twice daily for 14 days in each 28 day cycle (starting from Cycle 1) between Days 15-28
Age	Adult, Older_Adult

Cohort10: AZD6738_dose level1

Administration route	oral
Dosage	AZD6738, 160 mg, twice daily in Cycle 0 Days 1-7, followed by 7 days on treatment in each cycle between Days 22-28
Age	Adult, Older_Adult

Cohort11: AZD6738_dose level2_twice daily for 7 days

Administration route	oral
Dosage	AZD6738, 240 mg, twice daily for 7 days on Day 1-7 in each 28 day cycle
Age	Adult, Older_Adult

Overview of Knowledge Graph